The EGFR inhibitors cetuximab and panitumumab proved effective in RAS WT CRC (32, 33) and the BRAF inhibitor encorafenib demonstrated efficacy in the treatment of BRAF V600E mutant CRC (34). This evidence concerns the gene BRAF and colorectal carcinoma.